Hospital
Steward PGH, INC.
Steward PGH, INC. was paid $5.50M by Medicaid between Jun 2021 and Nov 2024, across 179 billing codes. Its largest line is 99284, emergency room visit (serious) — 27% of everything it billed.
33Billing provider infoSTEWARD PGH, INC.
HIALEAH, FL 33016
HIALEAH, FL 33016
33aNPI1497327233assigned 07/12/2021
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.50M
24GClaims198,608
24DCodes billed179
24AFirst – last monthJun 2021 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#79 of 163
Median peer was paid$4.77M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 48,612 | $1.66M | |
| 2022 | 96,783 | $2.27M | |
| 2023 | 40,281 | $1.23M | |
| 2024incomplete | 12,932 | $337K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 9,981 | 8,572 | $1.47M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 7,403 | 6,652 | $1.05M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 7,298 | 6,146 | $810K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 10% | 1,294 | 1,120 | $568K |
| 70450 | Computed tomography, head or brain; without contrast material | 9.7% | 1,513 | 1,240 | $534K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.6% | 623 | 547 | $364K |
| G0378 | Hospital observation service, per hour | 2.4% | 3,683 | 1,714 | $130K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 1,093 | 944 | $120K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 321 | 266 | $53K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,435 | 2,044 | $47K |
| 76818 | <1% | 444 | 265 | $38K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 307 | 290 | $33K |
167 more codes
| 59025 | Fetal non-stress test | <1% | 405 | $31K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 100 | $24K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 449 | $17K |
| 80053 | Comprehensive metabolic panel | <1% | 7,478 | $16K |
| 76830 | Ultrasound, transvaginal | <1% | 335 | $12K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,589 | $11K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 687 | $10K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,467 | $10K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,621 | $9K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,052 | $8K |
| 97161 | <1% | 283 | $8K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,073 | $7K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 370 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,812 | $7K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 6,483 | $7K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,006 | $7K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 338 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 844 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 288 | $4K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 15,017 | $4K |
| 10005 | <1% | 13 | $4K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 383 | $4K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 400 | $4K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 207 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,522 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,833 | $3K |
| 76801 | <1% | 557 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 665 | $3K |
| 82962 | <1% | 1,642 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,785 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,336 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,279 | $2K |
| 76641 | <1% | 62 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,222 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,190 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,095 | $1K |
| 85610 | <1% | 4,323 | $1K | |
| 87070 | <1% | 953 | $1K | |
| C1769 | Guide wire | <1% | 264 | $1K |
| 85730 | <1% | 4,022 | $1K | |
| 87040 | <1% | 1,212 | $1K | |
| 83880 | <1% | 929 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,871 | $1K |
| 73130 | <1% | 162 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 946 | $1K |
| 84703 | <1% | 1,419 | $1K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 27 | $983.88 |
| 84702 | <1% | 1,303 | $848.85 | |
| 71250 | <1% | 36 | $831.48 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 82 | $768.49 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,196 | $760.75 |
| 93971 | <1% | 137 | $745.25 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,002 | $740.38 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,186 | $719.46 |
| 72100 | <1% | 277 | $653.03 | |
| 93970 | <1% | 73 | $625.99 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 510 | $570.30 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 29 | $569.17 |
| 97165 | <1% | 34 | $489.41 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 861 | $474.14 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,643 | $445.57 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 682 | $364.15 |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 156 | $350.44 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,774 | $340.90 |
| 97162 | <1% | 14 | $336.29 | |
| 80047 | <1% | 39 | $335.24 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 478 | $326.44 |
| 81001 | <1% | 3,722 | $325.44 | |
| 83690 | <1% | 2,443 | $306.84 | |
| 73610 | <1% | 200 | $301.61 | |
| 90714 | <1% | 166 | $301.61 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 93 | $301.61 |
| 84484 | <1% | 3,757 | $294.08 | |
| 80061 | Lipid panel | <1% | 679 | $276.60 |
| 86850 | <1% | 1,283 | $273.42 | |
| 86900 | <1% | 1,424 | $249.65 | |
| 86901 | <1% | 1,421 | $233.22 | |
| 74018 | <1% | 262 | $227.56 | |
| 81025 | <1% | 988 | $210.08 | |
| 81003 | <1% | 1,651 | $185.00 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 686 | $134.19 |
| 87186 | <1% | 544 | $129.53 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 30 | $126.85 |
| 73562 | <1% | 206 | $124.52 | |
| 73630 | <1% | 258 | $115.47 | |
| 93976 | <1% | 13 | $107.86 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 185 | $95.25 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 191 | $90.67 |
| 00840 | <1% | 30 | $89.72 | |
| 73030 | <1% | 101 | $87.91 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,272 | $84.48 |
| 83605 | <1% | 805 | $74.49 | |
| 87088 | <1% | 1,083 | $74.14 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 866 | $72.54 |
| 85384 | <1% | 163 | $71.76 | |
| 83735 | <1% | 1,753 | $64.56 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 154 | $64.36 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 990 | $50.44 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 448 | $50.44 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 225 | $47.03 |
| 96376 | <1% | 664 | $37.98 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,295 | $34.78 |
| 82550 | <1% | 1,810 | $34.74 | |
| 85379 | <1% | 333 | $34.51 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,322 | $31.54 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 24 | $29.50 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 188 | $27.11 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 478 | $25.22 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 235 | $25.22 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 425 | $25.22 |
| 80076 | <1% | 1,826 | $24.02 | |
| 80050 | General health panel | <1% | 25 | $20.68 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 24 | $16.67 |
| 80143 | <1% | 154 | $13.12 | |
| 87400 | <1% | 819 | $9.28 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 656 | $8.60 |
| 84100 | <1% | 680 | $7.93 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 67 | $6.83 |
| 80179 | <1% | 141 | $6.56 | |
| 86140 | <1% | 45 | $6.33 | |
| 82150 | <1% | 121 | $3.15 | |
| 87205 | <1% | 331 | $2.28 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 21 | $1.11 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 113 | $0.60 |
| 84550 | 0% | 203 | $0.00 | |
| 82805 | 0% | 141 | $0.00 | |
| 84145 | 0% | 43 | $0.00 | |
| 84439 | 0% | 17 | $0.00 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | 0% | 16 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 742 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 297 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 384 | $0.00 |
| 83540 | 0% | 102 | $0.00 | |
| 73110 | 0% | 29 | $0.00 | |
| 87185 | 0% | 39 | $0.00 | |
| 85045 | 0% | 19 | $0.00 | |
| 85007 | 0% | 86 | $0.00 | |
| 88173 | 0% | 27 | $0.00 | |
| 84466 | 0% | 16 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 12 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 551 | $0.00 |
| 82607 | 0% | 194 | $0.00 | |
| 85027 | 0% | 124 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 106 | $0.00 |
| 87081 | 0% | 286 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 178 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 509 | $0.00 |
| 87077 | 0% | 414 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 153 | $0.00 |
| 82728 | 0% | 205 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 429 | $0.00 |
| A9270 | Non-covered item or service | 0% | 874 | $0.00 |
| 82746 | 0% | 118 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 16 | $0.00 |
| 83615 | 0% | 159 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 70 | $0.00 |
| 88331 | 0% | 13 | $0.00 | |
| 88304 | 0% | 32 | $0.00 | |
| 72170 | 0% | 19 | $0.00 | |
| 88307 | 0% | 18 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 14 | $0.00 |
| 88300 | 0% | 44 | $0.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 16 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 20 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 17 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 32 | $0.00 |
| 86592 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOLTZ, HERBERT (OFFICER, DIRECTOR, GENERAL COUNSEL)
| Provider | Location | Paid |
|---|---|---|
| Steward NSMC, INC. | Miami, FL | $5.76M |
| Steward HH. INC. | Hialeah, FL | $5.16M |
| Steward NSMC, INC. | Lauderdale Lakes, FL | $3.53M |
| Steward CGH, INC. | Coral Gables, FL | $2.40M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.